Intranodal pressure of a metastatic lymph node reflects the response to lymphatic drug delivery system.
Animals
Antineoplastic Agents
/ administration & dosage
Breast Neoplasms
/ drug therapy
Cell Line, Tumor
Disease Models, Animal
Drug Delivery Systems
Female
Humans
Immunohistochemistry
Lymph Nodes
/ pathology
Lymphatic Metastasis
Mice
Neovascularization, Pathologic
/ diagnostic imaging
Ultrasonography
/ methods
Xenograft Model Antitumor Assays
breast cancer
cancer treatment
drug delivery
intranodal pressure
lymph node metastasis
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
22
05
2020
revised:
21
08
2020
accepted:
27
08
2020
pubmed:
4
9
2020
medline:
22
12
2020
entrez:
4
9
2020
Statut:
ppublish
Résumé
Cancer metastasis to lymph nodes (LNs) almost certainly contributes to distant metastasis. Elevation of LN internal pressure (intranodal pressure, INP) during tumor proliferation is associated with a poor prognosis for patients. We have previously reported that a lymphatic drug delivery system (LDDS) allows the direct delivery of anticancer drugs into the lymphatic system and is a promising treatment strategy for early-stage LN metastasis. However, methods for evaluating the treatment effects have not been established. Here, we used a mouse model of MXH10/Mo-lpr/lpr, which develops a systemic swelling of LNs, and murine malignant fibrous histiocytoma-like (KM-Luc/GFP) cells or murine breast cancer (FM3A-Luc) cells inoculated into the subiliac LN of mice to produce a tumor-bearing LN model. The changes in INP during intranodal tumor progression and after treatment with cis-dichlorodiammineplatinum(II) (CDDP) using an LDDS were measured. We found that tumor progression was associated with an increase in INP that occurred independently of LN volume changes. The elevation in INP was suppressed by CDDP treatment with the LDDS when intranodal tumor progression was significantly inhibited. These findings indicate that INP is a useful parameter for monitoring the therapeutic effect in patients with LN metastasis who have been given drugs using an LDDS, which will serve to manage cancer metastasis treatment and contribute to an improved quality of life for cancer patients.
Identifiants
pubmed: 32882076
doi: 10.1111/cas.14640
pmc: PMC7648019
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4232-4241Subventions
Organisme : Japan Society for the Promotion of Science
ID : 17H00865 (TK)
Organisme : Japan Society for the Promotion of Science
ID : 17K13039 (SK)
Organisme : Japan Society for the Promotion of Science
ID : 17K20077 (TK)
Organisme : Japan Society for the Promotion of Science
ID : 19K16622 (SK)
Organisme : Japan Society for the Promotion of Science
ID : 19K22692 (KS)
Organisme : Japan Society for the Promotion of Science
ID : 19K22941 (TK)
Organisme : Japan Society for the Promotion of Science
ID : 20H00655 (TK)
Informations de copyright
© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
J Immunol Methods. 2015 Sep;424:100-5
pubmed: 26009246
Nat Genet. 2020 Jul;52(7):692-700
pubmed: 32451459
Cancer Res. 1992 Jan 15;52(2):487-90
pubmed: 1728421
Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4607-12
pubmed: 9539785
Cancer Med. 2019 May;8(5):2241-2251
pubmed: 30945479
Cancer Res. 2002 Feb 1;62(3):661-4
pubmed: 11830516
Cancer Sci. 2017 Nov;108(11):2115-2121
pubmed: 28846190
J Cancer. 2015 Oct 20;6(12):1282-94
pubmed: 26640589
Cancer Sci. 2016 Mar;107(3):224-32
pubmed: 26716604
Cancer Sci. 2020 Nov;111(11):4232-4241
pubmed: 32882076
Cancer Res. 1988 Dec 15;48(24 Pt 1):7022-32
pubmed: 3191477
Science. 2018 Mar 23;359(6382):1408-1411
pubmed: 29567714
Biochem Biophys Res Commun. 2015 May 8;460(3):543-8
pubmed: 25824032
J Clin Invest. 2014 Mar;124(3):922-8
pubmed: 24590277
Mutagenesis. 2010 May;25(3):281-8
pubmed: 20156843
Cancer Res. 2006 Nov 1;66(21):10365-76
pubmed: 17062557
Adv Drug Deliv Rev. 2001 Aug 23;50(1-2):3-20
pubmed: 11489331
Science. 2017 Jul 07;357(6346):55-60
pubmed: 28684519
Ultrasound Med Biol. 2015 Dec;41(12):3120-30
pubmed: 26411669
Annu Rev Biomed Eng. 2014 Jul 11;16:321-46
pubmed: 25014786
Cancer Sci. 2017 May;108(5):846-852
pubmed: 28211204
Ann Oncol. 2017 Sep 1;28(9):2135-2141
pubmed: 28911083
Ultrasound Med Biol. 2015 May;41(5):1411-21
pubmed: 25637527
Ultrasound Med Biol. 2014 Jun;40(6):1237-49
pubmed: 24656719
J Natl Cancer Inst. 2015 Jun 10;107(9):
pubmed: 26063793
Eur J Radiol. 2006 Jun;58(3):325-37
pubmed: 16464553
Cancer Res. 1990 Aug 1;50(15):4478-84
pubmed: 2369726
Science. 1966 Jun 3;152(3727):1397-8
pubmed: 5949244
J Clin Invest. 2018 Apr 2;128(4):1355-1370
pubmed: 29480816
Science. 2018 Mar 23;359(6382):1403-1407
pubmed: 29567713
PLoS One. 2015 Apr 21;10(4):e0123619
pubmed: 25897663
Ann Surg Oncol. 2011 Dec;18(13):3791-6
pubmed: 21626079
J Immunol Methods. 2013 Mar 29;389(1-2):69-78
pubmed: 23328410
Biomaterials. 2013 Mar;34(9):2277-88
pubmed: 23290525
J Immunol Methods. 2017 Jun;445:1-9
pubmed: 28237707
Sci Rep. 2019 Sep 13;9(1):13242
pubmed: 31519920
Cancer Res. 1998 Sep 1;58(17):3765-8
pubmed: 9731480